Protagonist Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PTGX Nasdaq 2830 www.protagonist-inc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protagonist Therapeutics, Inc.

High Growth Tech Stocks In The US For January 2026 - Jan 9th, 2026 4:38 am
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Jan 7th, 2026 7:10 pm
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Jan 7th, 2026 5:30 am
Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis - Jan 6th, 2026 2:29 pm
Takeda and Protagonist seek FDA approval for rusfertide to treat PV - Jan 6th, 2026 5:05 am
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Jan 5th, 2026 5:00 am
Three Stocks That May Be Undervalued In December 2025 - Dec 15th, 2025 4:38 am
High Growth Tech Stocks In The US Market With Potential - Dec 11th, 2025 4:38 am
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Dec 6th, 2025 7:30 am
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Dec 5th, 2025 2:21 pm
November 2025's Top Value Picks For Potential Market Opportunities - Nov 14th, 2025 10:38 am
High Growth Tech Stocks To Watch In The US This November 2025 - Nov 12th, 2025 4:38 am
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates - Nov 6th, 2025 3:45 pm
Protagonist Therapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 2:42 pm
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 6th, 2025 2:05 pm
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting - Nov 4th, 2025 3:09 pm
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? - Nov 4th, 2025 8:00 am
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Nov 4th, 2025 6:10 am
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Nov 3rd, 2025 2:05 pm
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Oct 30th, 2025 8:00 am